Aura Biosciences, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Aura Biosciences, Inc. (AURA) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $12.37 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-11
- Aura Biosciences, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $12.37M, a 222.67% increase year-over-year.
- Aura Biosciences, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $3.82M, a 8.82% increase year-over-year.
- Aura Biosciences, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $3.69M, a 34.11% increase year-over-year.
- Aura Biosciences, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $3.83M, a 22.62% increase year-over-year.
- Aura Biosciences, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $14.32M, a 22.14% increase from fiscal 2024.
- Aura Biosciences, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $11.72M, a 33.63% increase from fiscal 2023.
- Aura Biosciences, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $8.77M, a 36.81% increase from fiscal 2022.
- Aura Biosciences, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $6.41M, a 177.94% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $12.37M 10-Q · filed 2026-08-11 | $16.19M derived: sum of 2 quarters · filed 2026-08-11 | ||
| 2026-03-31 | $3.82M 10-Q · filed 2026-08-11 | |||
| 2025-12-31 | $14.32M 10-K · filed 2026-03-30 | |||
| 2025-09-30 | $3.69M 10-Q · filed 2025-11-13 | $7.52M derived: sum of 2 quarters · filed 2026-08-11 | $11.04M derived: sum of 3 quarters · filed 2026-08-11 | |
| 2025-06-30 | $3.83M 10-Q · filed 2026-08-11 | $7.35M derived: sum of 2 quarters · filed 2026-08-11 | ||
| 2025-03-31 | $3.51M 10-Q · filed 2026-08-11 | |||
| 2024-12-31 | $11.72M 10-K · filed 2026-03-30 | |||
| 2024-09-30 | $2.75M 10-Q · filed 2025-11-13 | $5.88M derived: sum of 2 quarters · filed 2025-11-13 | $8.79M derived: sum of 3 quarters · filed 2025-11-13 | |
| 2024-06-30 | $3.13M 10-Q · filed 2025-11-13 | $6.04M derived: sum of 2 quarters · filed 2025-11-13 | ||
| 2024-03-31 | $2.91M 10-Q · filed 2025-11-13 | |||
| 2023-12-31 | $8.77M 10-K · filed 2025-03-24 | |||
| 2023-09-30 | $2.33M 10-Q · filed 2024-11-12 | $4.26M derived: sum of 2 quarters · filed 2024-11-12 | $6.17M derived: sum of 3 quarters · filed 2024-11-12 | |
| 2023-06-30 | $1.93M 10-Q · filed 2024-11-12 | $3.84M derived: sum of 2 quarters · filed 2024-11-12 | ||
| 2023-03-31 | $1.91M 10-Q · filed 2024-11-12 | |||
| 2022-12-31 | $6.41M 10-K · filed 2024-03-27 | |||
| 2022-09-30 | $1.72M 10-Q · filed 2023-11-09 | $3.00M derived: sum of 2 quarters · filed 2023-11-09 | $4.60M derived: sum of 3 quarters · filed 2023-11-09 | |
| 2022-06-30 | $1.29M 10-Q · filed 2023-11-09 | $2.88M derived: sum of 2 quarters · filed 2023-11-09 | ||
| 2022-03-31 | $1.59M 10-Q · filed 2023-11-09 | |||
| 2021-12-31 | $2.31M 10-K · filed 2023-03-15 | |||
| 2021-09-30 | $554.00K 10-Q · filed 2022-11-10 | $825.00K derived: sum of 2 quarters · filed 2022-11-10 | $1.01M derived: sum of 3 quarters · filed 2022-11-10 | |
| 2021-06-30 | $271.00K 10-Q · filed 2022-11-10 | $456.00K derived: sum of 2 quarters · filed 2022-11-10 | ||
| 2021-03-31 | $185.00K 10-Q · filed 2022-11-10 | |||
| 2020-12-31 | $736.00K 10-K · filed 2022-03-23 | |||
| 2020-09-30 | $191.00K 10-Q · filed 2021-11-24 | $380.00K derived: sum of 2 quarters · filed 2021-11-24 | $557.00K derived: sum of 3 quarters · filed 2021-11-24 | |
| 2020-06-30 | $189.00K 10-Q · filed 2021-11-24 | $366.00K derived: sum of 2 quarters · filed 2021-11-24 | ||
| 2020-03-31 | $177.00K 10-Q · filed 2021-11-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |